The Society for Neuro-Oncology (SNO) is the field's main professional home in North America - a multidisciplinary non-profit bringing together neuro-oncologists, neurosurgeons, radiation oncologists, neuropathologists, neuroradiologists, basic scientists and allied health professionals working on tumors of the central nervous system. The society was organized in 1995 (following planning that began in late 1994 under Victor Levin) and is headquartered in Houston, Texas.

SNO is not a press. It does not typeset, host or sell its own journals; all four are published on its behalf by Oxford University Press, and three of them are co-owned with the European Association of Neuro-Oncology (EANO). In practice this means SNO sets editorial scope and appoints editors, while OUP supplies the submission platform, the licence menu, the price list, and the transformative-agreement coverage. When you submit, you are following OUP's author workflow inside a SNO-run editorial office.

The four titles are deliberately non-overlapping. Picking correctly at the start is the single biggest time-saver, because cross-journal transfers still cost weeks.

• Neuro-Oncology - launched as a quarterly in January 1999, moved to monthly publication and to Oxford University Press in 2010. It is the official journal of SNO and is additionally affiliated with EANO, the Asian Society for Neuro-Oncology (ASNO) and the Japan Society for Neuro-Oncology. It is the highest-profile venue in the specialty.
• Neuro-Oncology Advances - a fully open-access, interdisciplinary companion covering basic, applied and clinical CNS-cancer research, published jointly with EANO.
• Neuro-Oncology Practice - clinically oriented, aimed at practitioners and healthcare specialists managing patients with CNS tumors; also published with EANO.
• Neuro-Oncology Pediatrics - a fully open-access title dedicated to children and AYA patients with CNS tumors, supported by a grant from the Pediatric Brain Tumor Foundation with matched funding from EANO, and endorsed by ASNO and EANO.

The society also maintains a strategic affiliation with the Central Brain Tumor Registry of the United States (CBTRUS), whose annual statistical report appears as a Neuro-Oncology supplement, and runs Neuro-Oncology: The Podcast alongside its annual scientific meeting.

Because OUP is the publisher, SNO titles use OUP's licence menu: the standard OUP publishing licence for subscription articles, or CC BY / CC BY-NC (plus US Government and Crown Copyright variants) for open access. Prices are revised annually and vary by article type, so confirm on the journal's own charges page before you submit.

Two further routes reduce or remove the fee. Authors at institutions with an OUP Read & Publish agreement can usually publish OA with no direct charge - check the ESAC registry or your librarian. Authors in qualifying low- and middle-income countries receive OUP waivers or discounts, and EIFL's negotiated arrangement waives APCs for corresponding authors in its partner countries on OUP fully-OA journals. Colour figure charges of about $600 per figure apply separately on some titles regardless of route.

All four journals use single-anonymized peer review: reviewers see author identities, authors do not see reviewer identities. Manuscripts are normally assessed by at least two external experts, and Neuro-Oncology Advances asks reviewers to return reports within two weeks - one reason the OA companion often reaches a first decision faster than the flagship. Editorial offices are staffed by working neuro-oncologists, and desk rejection at Neuro-Oncology is common given its selectivity.

1. Choose the right title using the table above; scope mismatch is the most frequent avoidable rejection.
2. Read the journal's author instructions on Oxford Academic - each of the four has its own word limits, structured-abstract format, and figure rules.
3. Format your references in AMA numbered style, the house style across the family.
4. Submit through Editorial Manager - the platform for every SNO title (for example editorialmanager.com/n-o for Neuro-Oncology, /noa for Advances, /nop for Practice). Note that this is a change from older ScholarOne-based guidance still circulating online.
5. Pick your licence at acceptance, once you know whether a Read & Publish deal or waiver covers your charge.

As an Oxford University Press portfolio, the SNO journals follow COPE guidance on authorship, competing interests, corrections and retractions, and apply OUP's standard policies on clinical-trial registration, patient consent, and data availability. Trial reports are expected to follow CONSORT and to cite a prospective registration number. Author-facing policy pages sit on Oxford Academic rather than on the society's own site, so read the journal page, not just soc-neuro-onc.org, before submitting.